Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Integra LifeSciences Holdings Corporation    IART

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

(IART)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/16/2020 10/19/2020 10/20/2020 10/21/2020 10/22/2020 Date
48.46(c) 47.81(c) 47.75(c) 47.44(c) 48.26(c) Last
346 263 315 131 298 461 244 379 378 435 Volume
+1.06% -1.34% -0.13% -0.65% +1.73% Change
More quotes
Financials (USD)
Sales 2020 1 368 M - -
Net income 2020 46,3 M - -
Net Debt 2020 1 100 M - -
P/E ratio 2020 86,6x
Yield 2020 -
Sales 2021 1 524 M - -
Net income 2021 131 M - -
Net Debt 2021 883 M - -
P/E ratio 2021 31,5x
Yield 2021 -
Capitalization 4 067 M 4 067 M -
EV / Sales 2020 3,78x
EV / Sales 2021 3,25x
Nbr of Employees 4 000
Free-Float 79,4%
More Financials
Company
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and... 
More about the company
Notations Surperformance© of Integra LifeSciences Holdings Corporation
Trading Rating : Investor Rating :
More Ratings
All news about INTEGRA LIFESCIENCES HOLDINGS CORPORATION
10/07Oracle Cloud Observability and Management Platform Now Available
AQ
10/06INTEGRA LIFESCIENCES HOLDINGS CORP : Results of Operations and Financial Conditi..
AQ
10/06INTEGRA LIFESCIENCES : Announces Preliminary Third Quarter Revenue Results; Will..
AQ
10/06Integra LifeSciences Announces Preliminary Third Quarter Revenue Results; Wil..
GL
09/30SMITH & NEPHEW : +Nephew expands in higher-growth extremities segment through pl..
AQ
09/29SMITH & NEPHEW : Buys Extremity Orthopedics for $240 Million
DJ
09/29Smith & Nephew Plc Extremities Acquisition
DJ
09/29INTEGRA LIFESCIENCES HOLDINGS CORP : Entry into a Material Definitive Agreement,..
AQ
09/29SMITH & NEPHEW : Integra LifeSciences Announces Definitive Agreement to Divest i..
AQ
09/29Integra LifeSciences Announces Definitive Agreement to Divest its Extremity O..
GL
09/02Integra LifeSciences Announces September 2020 Investor Conference Schedule
GL
08/10INTEGRA LIFESCIENCES HOLDINGS CORP : Results of Operations and Financial Conditi..
AQ
08/10INTEGRA LIFESCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
08/10INTEGRA : 2Q Earnings Snapshot
AQ
08/10Integra LifeSciences Reports Second Quarter 2020 Financial Results
GL
More news
News in other languages on INTEGRA LIFESCIENCES HOLDINGS CORPORATION
08/05INTEGRA LIFESCIENCES HOLDINGS CORPOR : Veröffentlichung des Halbjahresergebnisse..
08/05INTEGRA LIFESCIENCES HOLDINGS CORPOR : publication des résultats semestriels
2017INTEGRA LIFESCIENCES : bringt Integra®SurgiMend(TM) PRS Meshed-Kollagenmatrix fü..
2017GNW-NEWS : Integra LifeSciences bringt Integra®SurgiMend(TM) PRS Meshed-Kollagen..
2017INTEGRA LIFESCIENCES : lance Integra® SurgiMend(TM) PRS Meshed Collagen Matrix p..
More news
Chart INTEGRA LIFESCIENCES HOLDINGS CORPORATION
Duration : Period :
Integra LifeSciences Holdings Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTEGRA LIFESCIENCES HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 59,46 $
Last Close Price 48,26 $
Spread / Highest target 55,4%
Spread / Average Target 23,2%
Spread / Lowest Target 3,61%
EPS Revisions
Managers
NameTitle
Peter J. Arduini President, Chief Executive Officer & Director
Stuart M. Essig Chairman
Glenn G. Coleman Chief Operating Officer & Vice President
Carrie Anderson Chief Financial Officer & Executive Vice President
Kenneth E. Burhop Chief Scientific Officer & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
INTEGRA LIFESCIENCES HOLDINGS CORPORATION-17.19%4 067
ABBOTT LABORATORIES26.04%187 552
MEDTRONIC PLC-1.42%146 850
BECTON, DICKINSON AND COMPANY-11.35%68 525
HOYA CORPORATION15.74%43 777
BAXTER INTERNATIONAL INC.-2.60%41 379